Tvardi Therapeutics, Inc. TVRD
Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026
Tvardi Therapeutics, Inc. (TVRD) is a healthcare company listed in the US with a market value of about $16M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -64%.
About Tvardi Therapeutics
Tvardi Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2014. Revenue went from $3M in 2014 to $7M in 2024, growth of about 8.4% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 74% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $7M | $21M | $42M | $23M | $135M | $20M | $13M | $911000 | $86000 |
| Net income | -$18M | -$29M | -$119M | -$85M | -$88M | $8M | -$106M | -$74M | -$58M | -$57M |
| Free cash flow | — | -$19M | -$94M | -$79M | -$60M | -$6M | -$109M | -$22M | -$55M | -$48M |
| EPS (diluted) | $-3.26 | $-11.42 | $-26.26 | $-19.12 | $-20.88 | $2.16 | $-29.88 | $-24.72 | $-22.32 | $-25.20 |
| Net margin | — | -411.9% | -565.2% | -204.2% | -384.1% | 6.2% | -534.9% | -549.5% | -6380.4% | -66604.7% |
| ROIC | -99.9% | — | — | -54.5% | -38.5% | 1.7% | -58.0% | -57.6% | -68.3% | -114.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $8.88, 652% above the current price; targets range from $3.00 to $14.00; the consensus rating is “Buy”; expected EPS is $-2.26 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Tvardi Therapeutics pay a dividend?
Not currently.
Is Tvardi Therapeutics a good stock to buy?
We do not give buy or sell advice. Tvardi Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.